Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring最新文献_第10页

Alteration of glucose neurometabolism and brain morphology in mild behavioral impairment: a neuroimaging study on cognitively healthy individuals. 轻度行为障碍患者葡萄糖神经代谢和脑形态的改变：认知健康个体的神经影像学研究

IF 4.4

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2026-07-16 eCollection Date: 2026-07-01 DOI: 10.1002/dad2.70425

Rafael Dolezal

{"title":"Alteration of glucose neurometabolism and brain morphology in mild behavioral impairment: a neuroimaging study on cognitively healthy individuals.","authors":"Rafael Dolezal","doi":"10.1002/dad2.70425","DOIUrl":"10.1002/dad2.70425","url":null,"abstract":"Introduction: Regional brain enlargement and increased glucose neurometabolism do not normally indicate neurodegeneration. Mild behavioral impairment (MBI) occurring in cognitively healthy individuals, however, might be significantly affected by these processes.Methods: Three hundred forty-one cognitively normal individuals were analyzed using partial least squares (PLS) regression to determine neurometabolic and brain volumetric determinants of MBI scores. Radiolabeled glucose non-displaceable binding potential and volumes of Schaefer homooxygenation parcels were screened as regressors. PLS models were evaluated with cross-validation, scrambling, and bootstrapping.Results: Hypermetabolism in the left entorhinal cortex and hypertrophy in the left dorsal attention network B contribute substantially to the MBI total score. Significant morpho-functional interactions were observed between the right middle temporal cortex and the right salience-ventral attention B network.Discussion: MBI might depend on cerebral bioenergetic processes and morpho-functional interactions. Relative hypermetabolism and hypertrophy could be considered specific biomarkers of MBI indicating a prodromal maladaptive neural response.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70425"},"PeriodicalIF":4.4,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13375937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148581393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world pharmacovigilance for anti-Aβ therapies using a large language model. 使用大语言模型的抗β治疗的现实世界药物警戒。

IF 4.4

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2026-07-16 eCollection Date: 2026-07-01 DOI: 10.1002/dad2.70412

Allan Fong, Azade Tabaie, Samantha Paylor, Tien Tran, Rabbiya Iqbal, Raj M Ratwani, Zafar Zafari, Lauren R Bangerter, Nicole J Brandt

{"title":"Real-world pharmacovigilance for anti-Aβ therapies using a large language model.","authors":"Allan Fong, Azade Tabaie, Samantha Paylor, Tien Tran, Rabbiya Iqbal, Raj M Ratwani, Zafar Zafari, Lauren R Bangerter, Nicole J Brandt","doi":"10.1002/dad2.70412","DOIUrl":"10.1002/dad2.70412","url":null,"abstract":"Introduction: Anti-amyloid beta (Aβ) therapies for early Alzheimer's disease require enhanced safety monitoring, yet adverse event (AE) documentation is diffuse across heterogeneous electronic health record documents. Large language models (LLMs) may improve scalable pharmacovigilance.Methods: We analyzed 20,123 clinical documents from 46 patients who received at least one dose of anti-Aβ therapy (June 24, 2024-July 30, 2025) at a large mid-Atlantic health-care system. We compared standard expert review versus an LLM-augmented workflow applied to the same documents. Expert reviewers annotated therapy-related AEs (e.g., amyloid-related imaging abnormalities with edema or hemorrhage, headache, syncope, hypersensitivity, gastrointestinal symptoms, infusion reactions). Discordant cases were adjudicated to establish a reference label.Results: After adjudication, 76% (35/46) patients had an AE. The LLM-augmented workflow achieved 100% sensitivity (positive predictive value [PPV] 89.7%) versus expert review 88.6% sensitivity (PPV 100%).Discussion: Findings provide preliminary indications that LLMs may serve as a pharmacovigilance signal detection tool, with a need for further validation and evaluation of clinical integration.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70412"},"PeriodicalIF":4.4,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13375930/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148581390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacogenetic analyses in people with dementia in Northeast Germany. 德国东北部痴呆症患者的药物遗传学分析。

IF 4.4

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2026-07-14 eCollection Date: 2026-07-01 DOI: 10.1002/dad2.70423

Marleen Julia Meyer-Tönnies, Leefke Schwarz, Diana Wucherer, Wolfgang Hoffmann, Jochen René Thyrian, Mladen Vassilev Tzvetkov

{"title":"Pharmacogenetic analyses in people with dementia in Northeast Germany.","authors":"Marleen Julia Meyer-Tönnies, Leefke Schwarz, Diana Wucherer, Wolfgang Hoffmann, Jochen René Thyrian, Mladen Vassilev Tzvetkov","doi":"10.1002/dad2.70423","DOIUrl":"10.1002/dad2.70423","url":null,"abstract":"Introduction: Pharmacogenetics-guided prescribing may reduce adverse drug reactions by 30%. European and American expert groups (Dutch Pharmacogenetics Working Group and Clinical Implementation Consortium) issue genotype-based dosage recommendations, but pharmacogenetic testing is still not routinely used. Here, we assess the potential of pharmacogenetic testing to optimize pharmacotherapy in people with dementia (PwD).Methods: We genotyped variants in CYP2D6 , CYP2C9, CYP2C19, CYP3A4, CYP3A5, and SLCO1B1 genes and related them to individual medication data in 115 PwD from an epidemiological cohort from Northeast Germany.Results: The vast majority of PwD (93%) carried at least one actionable variant. Fourteen (12%) had at least one strongly actionable variant. Four of them (4%) took the drug affected and carried the strongly actionable genetic variant.Discussion: Pharmacogenetic testing may contribute to improved pharmacotherapy in PwD. The potential improvements were mainly for medications commonly taken by elderly, but also for medications used to treat or associated with progression of dementia.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70423"},"PeriodicalIF":4.4,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13368705/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148457785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of plasma irisin levels with amyloid burden in the Alzheimer's disease spectrum. 血浆鸢尾素水平与阿尔茨海默病谱系中淀粉样蛋白负荷的关系

IF 4.4

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2026-07-13 eCollection Date: 2026-07-01 DOI: 10.1002/dad2.70418

Young Hee Jung, Eun Seong Lee, Yu Jeong Park, Seungyun Lee, Su Jin Chung, Jin Ju Lim, Seon Wook Kim, Ho Jin Kang, Jae Seon Eo, Kyungmi Oh, Seong-Beom Koh, Hyeon Soo Kim, Sung Hoon Kang

{"title":"Association of plasma irisin levels with amyloid burden in the Alzheimer's disease spectrum.","authors":"Young Hee Jung, Eun Seong Lee, Yu Jeong Park, Seungyun Lee, Su Jin Chung, Jin Ju Lim, Seon Wook Kim, Ho Jin Kang, Jae Seon Eo, Kyungmi Oh, Seong-Beom Koh, Hyeon Soo Kim, Sung Hoon Kang","doi":"10.1002/dad2.70418","DOIUrl":"10.1002/dad2.70418","url":null,"abstract":"Introduction: This study investigated the association between plasma myokines, including irisin, and cerebral amyloid burden across the Alzheimer's disease (AD) continuum.Methods: A total of 100 participants were classified into four groups: amyloid-negative cognitively unimpaired (A- CU), amyloid-positive CU (A+ CU), A+ mild cognitive impairment (MCI), and A+ dementia of the Alzheimer's disease type (DAT). All participants underwent neuropsychological testing, brain magnetic resonance imaging, amyloid positron emission tomography, and plasma myokine assessment. Multivariable linear regression and mediation analyses were performed adjusting for covariates.Results: Irisin levels were significantly lower in all AD continuum groups compared to A- CU participants (p < 0.001), while brain-derived neurotrophic factor (BDNF) and fibroblast growth factor 21 (FGF21) showed no group differences. Higher irisin levels were associated with lower amyloid burden (r = -0.24, p = 0.019). Mediation analysis demonstrated that amyloid burden mediated the relationship between irisin and cognitive outcomes, whereas no such effects were observed for BDNF or FGF21.Discussion: Irisin may play a key role in the muscle-brain axis by linking amyloid pathology to cognitive decline in AD.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70418"},"PeriodicalIF":4.4,"publicationDate":"2026-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13364751/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148450521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

APOE ε4 and Alzheimer's disease biomarkers in an American Indian community. APOE ε4与美国印第安人社区阿尔茨海默病的生物标志物

IF 4.4

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2026-07-13 eCollection Date: 2026-07-01 DOI: 10.1002/dad2.70421

Matti J Matheson, Rene Labounek, Adam D Block, Corey Strong, Ann J Robertson, Adam Hansen, Meghan Kremer, Ashley J Petersen, Annamarie Hill, Breton M Asken, Igor Nestrasil, Christophe Lenglet, Danni Li, J Neil Henderson, William G Mantyh

{"title":"APOE ε4 and Alzheimer's disease biomarkers in an American Indian community.","authors":"Matti J Matheson, Rene Labounek, Adam D Block, Corey Strong, Ann J Robertson, Adam Hansen, Meghan Kremer, Ashley J Petersen, Annamarie Hill, Breton M Asken, Igor Nestrasil, Christophe Lenglet, Danni Li, J Neil Henderson, William G Mantyh","doi":"10.1002/dad2.70421","DOIUrl":"10.1002/dad2.70421","url":null,"abstract":"Introduction: Apolipoprotein E (APOE) ε4's effect on Alzheimer's disease (AD) depends on ancestry and environmental risk factors. The APOE ε4-AD link in American Indian (AI) populations appears attenuated, with current understanding largely informed by a single research study. This study seeks to extend this evidence in an AI population in Minnesota.Methods: Cross-sectional analysis of APOE ε4, medical comorbidities, and AD plasma biomarkers with 182 tribal elders.Results: Median age was 67; 70% were female; median Mini-Mental State Examination score was 29. Age-, sex-, and chronic kidney disease-adjusted log odds ratios with 95% confidence intervals for APOE ε4 carrier status on amyloid beta 42/40, tau phosphorylated at threonine 217 (p-tau217), and glial fibrillary acidic protein (GFAP) were 0.86 (0.80 to 0.94), 1.04 (0.87 to 1.25), and 1.00 (0.86 to 1.16).Conclusion: Compared to non-Hispanic White populations, APOE ε4 has an attenuated effect on p-tau217 or GFAP in AI tribal elders. Limitations of this study include survival bias and race-associated differences in social determinants of health that can influence the observed results.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70421"},"PeriodicalIF":4.4,"publicationDate":"2026-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13358808/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148438876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preparedness and quality of dementia care in an Italian health authority when introducing anti-Aβ therapies. 意大利卫生当局在引入抗a β疗法时痴呆护理的准备和质量。

IF 4.4

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2026-07-13 eCollection Date: 2026-07-01 DOI: 10.1002/dad2.70403

Maurizio Giorelli, Claudia Ada Di Paola, Rosangela Vallarelli, Francesco Negri, Rosalba Morgese, Rosario Francesco Balzano, Pasquale Di Fazio, Daniela Tatò, Cataldo Procacci, Gianluca Masi, Federica Lucia Carpagnano, Tiziana Dimatteo

{"title":"Preparedness and quality of dementia care in an Italian health authority when introducing anti-Aβ therapies.","authors":"Maurizio Giorelli, Claudia Ada Di Paola, Rosangela Vallarelli, Francesco Negri, Rosalba Morgese, Rosario Francesco Balzano, Pasquale Di Fazio, Daniela Tatò, Cataldo Procacci, Gianluca Masi, Federica Lucia Carpagnano, Tiziana Dimatteo","doi":"10.1002/dad2.70403","DOIUrl":"10.1002/dad2.70403","url":null,"abstract":"Introduction: We aimed to assess dementia care organizations within a southern Italian local health authority (Azienda Sanitaria Locale di Barletta Andria Trani) and to propose an equitable implementation framework for anti-amyloid therapies.Methods: We performed a retrospective analysis of dementia-related outpatient activity in 2024 patients across 18 district clinics (primary care clinics) and three specialized centers for cognitive disorders and dementia (specialized memory centers), integrating booking, clinical, imaging, and prescribing data.Results: Among 1158 initial evaluations, specialized memory centers showed substantially higher quality indicators than district clinics: Mini-Mental State Examination documentation (80.0% vs. 6.6%, p < 0.001), full clinical documentation (95.5% vs. 10.0%), higher use of magnetic resonance imaging and amyloid positron emission tomography, and 5-fold higher rate of prescribing acetylcholinesterase inhibitors. Validated radiological scoring and biomarker facilities (cerebrospinal fluid, apolipoprotein E genotyping) were largely unavailable.Discussion: Major organizational gaps limit readiness for disease-modifying Alzheimer's disease therapies. A four-tier hub-and-spoke model may improve equity, efficiency, and safe implementation.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70403"},"PeriodicalIF":4.4,"publicationDate":"2026-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13364749/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148450438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Associations among mild behavioral impairment, cognition, and brain pathology in preclinical autosomal dominant Alzheimer's disease. 临床前常染色体显性阿尔茨海默病中轻度行为障碍、认知和脑病理的关系

IF 4.4

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2026-07-13 eCollection Date: 2026-07-01 DOI: 10.1002/dad2.70424

Catarina Tristão-Pereira, Daniel Vasquez, Jorge Alcina, Ana Baena, David Aguillon, Paula Ospina Lopera, Natalia Londono, Claudia Ramos, Lusiana Martinez, Sergio Alvarez, Monica Vidal, Isabela Gonzalez, Vincent Malotaux, Bing He, Averi Giudicessi, Liliana Ramirez-Gomez, Jennifer Gatchel, Zahinoor Ismail, Yakeel T Quiroz

{"title":"Associations among mild behavioral impairment, cognition, and brain pathology in preclinical autosomal dominant Alzheimer's disease.","authors":"Catarina Tristão-Pereira, Daniel Vasquez, Jorge Alcina, Ana Baena, David Aguillon, Paula Ospina Lopera, Natalia Londono, Claudia Ramos, Lusiana Martinez, Sergio Alvarez, Monica Vidal, Isabela Gonzalez, Vincent Malotaux, Bing He, Averi Giudicessi, Liliana Ramirez-Gomez, Jennifer Gatchel, Zahinoor Ismail, Yakeel T Quiroz","doi":"10.1002/dad2.70424","DOIUrl":"10.1002/dad2.70424","url":null,"abstract":"Introduction: The Mild Behavioral Impairment Checklist (MBI-C) captures neuropsychiatric symptoms in individuals at risk of dementia. In this study, we examined MBI-C scores in autosomal dominant Alzheimer's disease (ADAD).Methods: We included 83 cognitively unimpaired presenilin-1 E280A mutation carriers and 114 non-carriers with MBI-C, obfjective cognition, and subjective cognitive decline (SCD) assessments. Study sub-samples underwent neuroimaging to assess Alzheimer's disease (AD) pathology and neurodegeneration.Results: MBI-C total scores were greater in carriers than non-carriers (r rb = 0.19 [95% confidence interval (CI) 0.05, 0.31], P = 0.009), driven by impulse dyscontrol symptoms. Elevated MBI-C scores were associated with higher study partner-reported SCD scores (β = 0.28 [95% CI 0.07, 0.050], P = 0.008) and with greater neocortical amyloid beta (β = 0.46 [95% CI 0.17, 0.075], P = 0.003) among carriers.Discussion: Our study reveals that mild behavioral impairment symptoms may emerge before cognitive decline in ADAD and supports the MBI-C as a tool for detecting early behavioral changes linked to AD pathology and identifying at-risk individuals for clinical trials and early intervention.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70424"},"PeriodicalIF":4.4,"publicationDate":"2026-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13358810/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148438856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of a multi-analyte algorithmic immunoassay blood test with immunoprecipitation mass spectrometry for the detection of amyloid pathology. 多分析物算法免疫测定血液试验与免疫沉淀质谱法检测淀粉样蛋白病理的比较。

IF 4.4

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2026-07-09 eCollection Date: 2026-07-01 DOI: 10.1002/dad2.70420

David Wilson, Karen Copeland, Lindsey Mette, Meenakshi Khare, Matt Polak, Jorge Marques Signes, Tim Skelton

{"title":"Comparison of a multi-analyte algorithmic immunoassay blood test with immunoprecipitation mass spectrometry for the detection of amyloid pathology.","authors":"David Wilson, Karen Copeland, Lindsey Mette, Meenakshi Khare, Matt Polak, Jorge Marques Signes, Tim Skelton","doi":"10.1002/dad2.70420","DOIUrl":"10.1002/dad2.70420","url":null,"abstract":"Introduction: Alzheimer's blood-based biomarker (BBM) tests using single biomarkers or ratios are well characterized, but head-to-head comparisons of multi-analyte algorithmic tests on shared cohorts are lacking. We compared a five-biomarker algorithmic immunoassay (LucentAD Complete) with an algorithmic immunoprecipitation mass-spectrometry (IP-MS) benchmark on a shared plasma cohort.Methods: Symptomatic individuals (n = 192) with longitudinal samples from Alzheimer's Disease Neuroimaging Initiative (ADNI) were analyzed versus amyloid positron emission tomography (PET). Cross-sectional (n = 115) and longitudinal (n = 179; 12-year span) cohorts representing disease progression were used.Results: The immunoassay amyloid risk score demonstrated a 0.94 area under the curve (AUC) and 92%-93% accuracy, achieving performance parity with IP-MS metrics on shared samples. The two-cutoff design yielded an intermediate zone of 10.4%-12.8%.Discussion: These results establish diagnostic parity between algorithmic immunoassay and algorithmic IP-MS assay. In addition, providing individual biomarker results alongside a validated risk score offers a more granular foundation for comprehensive management than amyloid status alone, supporting premium reimbursement for multi-analyte algorithmic BBMs in clinical practice.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70420"},"PeriodicalIF":4.4,"publicationDate":"2026-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13351331/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148425412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Independent prognostic value of peak width of skeletonized mean diffusivity on clinical progression in Alzheimer's disease. 骨化平均弥散度峰宽对阿尔茨海默病临床进展的独立预后价值。

IF 4.4

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2026-07-08 eCollection Date: 2026-07-01 DOI: 10.1002/dad2.70416

Jonas Alexander Jarholm, Sandra Tecelão, Bjørn-Eivind Kirsebom, Mostafa Mehdipour Ghazi, Lene Pålhaugen, Berglind Gísladóttir, Fernando Gonzalez-Ortiz, Mehdi Sadat Akhavi, Einar Hopp, Anders Martin Fjell, Santiago Timón-Reina, Mads Nielsen, Kaj Blennow, Dag Aarsland, Atle Bjørnerud, Per Selnes, Tormod Fladby

{"title":"Independent prognostic value of peak width of skeletonized mean diffusivity on clinical progression in Alzheimer's disease.","authors":"Jonas Alexander Jarholm, Sandra Tecelão, Bjørn-Eivind Kirsebom, Mostafa Mehdipour Ghazi, Lene Pålhaugen, Berglind Gísladóttir, Fernando Gonzalez-Ortiz, Mehdi Sadat Akhavi, Einar Hopp, Anders Martin Fjell, Santiago Timón-Reina, Mads Nielsen, Kaj Blennow, Dag Aarsland, Atle Bjørnerud, Per Selnes, Tormod Fladby","doi":"10.1002/dad2.70416","DOIUrl":"10.1002/dad2.70416","url":null,"abstract":"Introduction: Peak width of skeletonized mean diffusivity (PSMD) is a candidate magnetic resonance imaging marker for global white matter integrity. We investigated the value of PSMD in predicting clinical progression in amyloid-positive and amyloid-negative individuals.Methods: PSMD, cognition, and amyloid status were measured in 254 subjects from the Dementia Disease Initiation (DDI) cohort and 211 subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. Survival analysis was conducted on 166 DDI subjects and validated in 178 ADNI subjects using Clinical Dementia Rating scale.Results: High PSMD amyloid-positive individuals had an increased risk of clinical progression relative to those with low PSMD, driven by independent additive effects of amyloid pathology and PSMD. Higher PSMD was predominantly associated with slower processing speed and reduced executive function, but not with memory performance.Discussion: Combining PSMD with amyloid status may improve the prediction of clinical progression in Alzheimer's disease, particularly in relation to executive and processing speed domains.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70416"},"PeriodicalIF":4.4,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13344884/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148413803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relationships between longitudinal retinal amyloid imaging and amyloid PET in the A4 Trial. A4试验中纵向视网膜淀粉样蛋白成像与淀粉样蛋白PET之间的关系。

IF 4.4

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2026-07-08 eCollection Date: 2026-07-01 DOI: 10.1002/dad2.70422

Sonal Sukreet, Michael C Donohue, Jennifer Ngolab, Alison Belsha, Jennifer Salazar, Paula Cohen, Sandhya Jaiswal, Veasna Tan, Neelum T Aggarwal, Jessica Alber, Ken Johnson, Gregory A Jicha, Christopher H van Dyck, Srinath Ramanan, James J Lah, Stephen Salloway, Steven R Verdooner, Michael S Rafii, Paul S Aisen, Reisa A Sperling, Robert A Rissman

{"title":"Relationships between longitudinal retinal amyloid imaging and amyloid PET in the A4 Trial.","authors":"Sonal Sukreet, Michael C Donohue, Jennifer Ngolab, Alison Belsha, Jennifer Salazar, Paula Cohen, Sandhya Jaiswal, Veasna Tan, Neelum T Aggarwal, Jessica Alber, Ken Johnson, Gregory A Jicha, Christopher H van Dyck, Srinath Ramanan, James J Lah, Stephen Salloway, Steven R Verdooner, Michael S Rafii, Paul S Aisen, Reisa A Sperling, Robert A Rissman","doi":"10.1002/dad2.70422","DOIUrl":"10.1002/dad2.70422","url":null,"abstract":"Introduction: Alzheimer's disease (AD) is associated with retinal amyloid-related changes, which may help identify amyloid positron emission tomography (PET) positive (+) individuals. Previously, in a small cross-sectional study, we reported higher retinal spot counts (RSCs) in preclinical amyloid PET (+) individuals screened for the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial compared to control individuals enrolled in the Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) trial before drug treatment.Methods: Eligible volunteers had retinal scans 48 hours after consuming curcumin. Scans were processed and quantified via NeuroVision. Participants were grouped by amyloid status and treatment to assess the effect of solanezumab on RSC.Results: RSC did not differ significantly over time between groups and was not modified by treatment, diverging from the cross-sectional retinal amyloid findings observed in A4/LEARN.Discussion: Curcumin-based retinal amyloid labeling shows promise but needs standardized protocols and validation in larger cohorts to understand its relationship to amyloid PET.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70422"},"PeriodicalIF":4.4,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13344897/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148413820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0